Discovery and optimization of N-phenylbenzenesulfonamide analogues as novel ALKBH5 inhibitors for AML therapy
- 20 October 2026
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 184, 110658
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
This publication has 26 references indexed in Scilit:
- Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effectBioorganic & Medicinal Chemistry, 2026
- Discovery of maleimide derivatives as m6A demethylase ALKBH5 inhibitorsBioorganic & Medicinal Chemistry, 2025
- Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5European Journal of Medicinal Chemistry, 2024
- Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AMLJournal of Medicinal Chemistry, 2023
- Chemical Inhibitors Targeting the Oncogenic m6A Modifying ProteinsAccounts of Chemical Research, 2023
- ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability controlCell Reports, 2023
- N 6 -Methyladenosine and Its Implications in VirusesGenomics, Proteomics & Bioinformatics, 2022
- Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5European Journal of Medicinal Chemistry, 2022
- Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling AxisCell Stem Cell, 2020
- RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid LeukemiaCell Stem Cell, 2020